Data on quantification of signaling pathways activated by KIT and PDGFRA mutants  by Bahlawane, Christelle et al.
Contents lists available at ScienceDirect
Data in Brief
Data in Brief 9 (2016) 828–838http://d
2352-34
(http://c
DOI
n Corr
E-mjournal homepage: www.elsevier.com/locate/dibData ArticleData on quantiﬁcation of signaling pathways
activated by KIT and PDGFRA mutants
Christelle Bahlawane a,n, Martine Schmitz a, Elisabeth Letellier a,
Karthik Arumugamb, Nathalie Nicot c, Petr V. Nazarov c,
Serge Haan a
a Molecular Disease Mechanisms group, Life Sciences Research Unit, University of Luxembourg, Campus
Belval, 6 Avenue du Swing, L-4367 Belvaux, Luxembourg
b Department of Infection and Immunity, LIH, 84 Val Fleuri, L-1526 Luxembourg
c Genomics Research Unit, LIH, 84 Val Fleuri, L-1526 Luxembourga r t i c l e i n f o
Article history:
Received 19 October 2016
Received in revised form
21 October 2016
Accepted 26 October 2016
Available online 2 November 2016
Keywords:
c-KIT
PDGFRα
MAPK
PI3K
Gastro-intestinal stromal tumours
PD0325901
Stem cell factorx.doi.org/10.1016/j.dib.2016.10.026
09/& 2016 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
esponding author. Fax: þ352 4666446435
ail addresses: christelle.bahlawane@uni.lu,a b s t r a c t
The present data are related to the article entitled “Insights into
ligand stimulation effects on gastro-intestinal stromal tumors
signaling” (C. Bahlawane, M. Schmitz, E. Letellier, K. Arumugam, N.
Nicot, P.V. Nazarov, S. Haan, 2016) [1]. Constitutive and ligand-
derived signaling pathways mediated by KIT and PDGFRA mutated
proteins found in gastrointestinal stromal tumors (GIST) were
compared. Expression of mutant proteins was induced by dox-
ycycline in an isogenic background (Hek293 cells). Kit was iden-
tiﬁed by FACS at the cell surface and found to be quickly degraded
or internalized upon SCF stimulation for both Kit Wild type and Kit
mutant counterparts. Investigation of the main activated pathways
in GIST unraveled a new feature speciﬁc for oncogenic KIT
mutants, namely their ability to be further activated by Kit ligand,
the stem cell factor (scf). We were also able to identify the MAPK
pathway as the most prominent target for a common inhibition of
PDGFRA and KIT oncogenic signaling. Western blotting and micro-
array analysis were applied to analyze the capacities of the mutant
to induce an effective STATs response. Among all Kit mutants, onlyvier Inc. This is an open access article under the CC BY license
/j.cellsig.2016.10.009
.
christelle@bahlawane.eu (C. Bahlawane).
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C. Bahlawane et al. / Data in Brief 9 (2016) 828–838 829Kit Ex11 deletion mutant was able to elicit an effective STATs
response whereas all PDGFRA were able to do so.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcation Tableubject area Cancer Research
ore speciﬁc sub-
ject areaSignal transduction AND Receptor Tyrosine Kinasesype of data Western blot; qPCR, FACS, micro-array, Computational modeling
ow data was
acquiredFusion-FX7 chemiluminescence detection device (Vilber) for Western
blotting,
CLARIOstar microplate reader (BMG LABTECH) for ﬂuorescence measure-
ments of cell viability
GeneChip Human Gene ST 2.0 arrays (Affymetrix) for micro-array
FACS CantoII Instrument (Becton Dickinson, Heidelberg, Germany) for ﬂow
cytometry
Model building and reﬁnement with CHARMMxperimental
featuresKIT and PDGFRA mutants were expressed in hek293 cell lines upon dox-
ycycline addition
Experiments were performed with/without ligand inductionata source location LIH, Luxembourg and university of Luxembourg, Luxembourg
ata accessibility Data are available in the article, and at ArrayExpress E-MTAB-4548D
Value of the data
 Expression of different mutant proteins (Kit and PDGFRA) in an isogenic background to allow a
direct comparison of their signalling capacities, without the complex patient speciﬁc- background.
The constructs and/or the Hek293 cell lines, could be used for further molecular characterization,
protein-protein interaction experiments or protein localization studies. Identiﬁed mutations in
GIST could easily be investigated by insertion of the newly discovered mutation in the WT
constructs by site-directed mutagenesis. Plasmids are available upon request.
 Identiﬁcation of a new feature speciﬁc to Kit mutants: their ability to be further stimulated by their
natural ligand, in addition to their constitutive activation derived from the mutations observed
in GIST.
 A new MEK inhibitor (PD0325901) was identiﬁed to be efﬁcient in inhibiting GIST cell proliferation
in the nanomolar range.1. Data
The data presented here derived mainly from western blot analysis for the quantiﬁcation of sig-
naling pathways activated by KIT and PDGFRA mutants, from micro-array analysis for quantiﬁcation
of changes in gene expression levels induced by the different mutations and from ﬂow cytometry
analysis for the detection of KIT at the cell surface.
Doxycycline induces Kit expression by a factor 100 in all cell lines and comparable mRNA
expression levels were observed for all mutants (Fig. 1a). However, some differences in the protein
expression levels were observed between the different constructs (Fig. 1b).
The ratio of surface (Fig. 1a in [1]) to total KIT expression (Fig. 1b in [1]) indicates that KIT WT is
expressed almost exclusively at the surface, while this is the case for 70% of KIT Ex9. This value drops
Fig. 1. KIT RNA and protein expression levels in the stable transfected cells. (a) KIT mRNA expression level as assessed by qPCR
in Hek293 cells expressing KIT WT, KIT Ex11, KIT Ex9 and KIT V559D 14 h after induction with doxycycline (5 ng/ml). SCF was
added at 100 ng/ml for the time of induction. Data represent the means of 3–6 biological replicates and are normalized using
Genorm following the MIQE guidelines [2]. (b) Western blot analysis indicating KIT expression level as well as phosphorylation
status in Hek293 cells expressing KIT WT, KIT Ex11, KIT Ex9 and KIT V559D 14 h after induction with doxycycline (5 ng/ml). SCF
was added at 100 ng/ml for the time of induction or 5 min before cell harvesting as indicated on the ﬁgure. Representative data
of 3 biological replicates. STAT5 is used as loading control.
Fig. 2. Effect of ligand stimulation on KIT expression at the cell surface.
C. Bahlawane et al. / Data in Brief 9 (2016) 828–838830to 50% for both Ex11 mutants. The results of the FACS analysis after SCF stimulation (Fig. 2) indicate
the decrease of KIT expression at the cell surface for all KIT mutants and wild type following sti-
mulation with KIT ligand, SCF.
Fig. 3. Effect of ligand stimulation on downstream signaling in GIST mutants. (a) Western blot analysis indicating the phos-
phorylation status of KIT/PDGFRα, STAT5, Akt and Erk in Hek293 cells expressing PDGFRα WT, PDGFRα V561D, KIT WT, KIT
Ex11, KIT Ex9 and KIT V559D after PDGFAA or SCF addition. Representative blots of 3 biological replicates. Tubulin is used as
loading control. (b) Quantiﬁcation of the signal intensities from the western blots shown in a. Data were calibrated using the
sample “KIT WT non-stimulated” (background level), except for PDGFRA phosphorylation where PDGFRa WT non-stimulated
was used. Each dot represents the mean of biological triplicates and the error bars the standard error of the mean. From left to
right, bars represent the signal intensities after ligand addition (1st bars correspond to no ligand, 15 and 60 min after ligand
addition are marked for better visibility).
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Fig. 3. (continued)
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Fig. 4. Activation of STAT species by GIST mutants. (a) Nuclear translocation of STAT species. Nuclear extracts were prepared as
previously done [4], diluted in 4 times Laemmli buffer and subjected to Western blot analysis. Phosphorylation status of STAT5,
STAT3 and STAT1 is shown for nuclear extract prepared from Hek293 cells expressing KIT WT, KIT Ex11, KIT Ex9 and KIT V559D.
(b) Induction of known STAT target genes by GIST mutants. Gene expression level of known STAT target genes, previously
identiﬁed to be induced in PDGFRA GIST mutants [3], was retrieved from micro-array data and presented as heat map. Grey
boxes indicate that the genes are not part of the DEG list for the corresponding mutant (FDR40.05 or AbsFCo0.5). The
intensity of the red color corresponds to the value of the ratio to the background (Hek293 KIT WT non-stimulated for KIT WT
and mutants and Hek293 PDGFRα non-stimulated for PDGFRα mutants). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article) .
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Fig. 5. Synergistic assessment for PD0325901 and XL184 inhibitors in GIST882.
C. Bahlawane et al. / Data in Brief 9 (2016) 828–838834The Mean Fluorescence Intensity (MFI) of Kit staining in the different Kit mutants are indicated in
Table 1.
While PDGFRα, Akt, and Erk phosphorylation were induced by PDGFAA in PDGFRaWT, phos-
phorylation of PDGFRα, Akt, Erk and STAT5 remained identical to the non-stimulated control for the
PDGFRA mutant V591D, as previously shown [3]. In contrast, Kit mutants exhibit all constitutive
phosphorylation of kit at tyrosine 703 but the signal intensities for Erk, Akt and STAT5 phosphor-
ylation was further increased upon SCF stimulation (Fig. 3a and Fig. 3b).
STATs translocation to the nucleus was identiﬁed for Kit Ex11 deletion mutant and for Kit Ex9
duplication mutant to a lower extend. Induction of gene expression known to be part of the STAT
pathway was found for Kit Ex11 deletion mutant after SCF stimulation as well as for Kit Ex9 dupli-
cation mutant upon SCF stimulation to a lower extend (Fig. 4a and Fig. 4b).
We investigated KIT Ex11 speciﬁc gene signature, comparing KIT Exon 11 deletion mutant regu-
lated genes to other GIST mutants (PDGFRA mutants and KIT Exon 9). 277 genes (Table 3) were
differentially expressed in KIT Ex11 deletion mutant only. As noted in [1], these genes were associated
with “cell cycle” and “insulin signalling pathway”.
Both inhibitors were added to the medium 24 h after seeding for 30 h. Both drugs were added
individually and in combination with a constant ratio of 1:1 (Fig. 5). Viability was assessed using
PrestoBlue following the manufacturer's recommendation. Results were analysed using the Compu-
syn software [5] and the combination Index (CI) values are represented as a function of the per-
centage of inhibition. CI values below 1 indicates a synergy between the two compounds, while CI
values above 1 indicates antagonism.
GIST882 were treated with 100 nM imatinib for different times and mRNA expression level of
ETV4, ETV5, egr1, FosL2 and FosB were assessed by qPCR. n¼ 3, Mean7SEM (Fig. 6).
qPCR primers are listed in Table 2.2. Experimental design, materials and methods
2.1. Flow cytometry analysis
Cell surface expression of KIT wild type and mutants was analyzed by ﬂow cytometry using a FACS
CantoII Instrument (Becton Dickinson, Heidelberg, Germany) either without ligand (blue lines) or 15
minutesmin after stimulation with 100ng/ml100 ng/ml SCF (pink lines). Cells were then either
incubated with 10 μL KIT primary antibody (anti-CD117-APC conjugated; C7244; Dako, Belgium) for
cell surface expression. Speciﬁcity was controlled using an isotype-matched/ APC conjugated anti-
body (grey).
Table 1
Mean Fluorescence Intensity (MFI) of Kit staining in the different Kit mutants.
MFI Kit WT Kit V559D Kit Ex9 Kit ex11
SCF þSCF SCF þSCF SCF þSCF SCF þSCF
Surface 2099 111 172 11 1435 284 562 222
Overall
expression
2122 642 374 319 2106 1355 1008 852
ETV 4 ETV 5
0.0
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1.5
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Fig. 6. Imatinib effect on MAPK gene expression level over time.
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Cell lysis was performed on ice, using 1x Laemmli buffer. Proteins were subjected to SDS-PAGE,
transferred to polyvinylidene diﬂuoride membranes (Roth) and probed with primary antibodies.
Primary antibodies against PLCγ and phosphospeciﬁc antibodies against STAT1 (pTyr701), STAT3
(pTyr705), ERK1/2 (pThr202/pTyr204), PDGFRA (pTyr849)/β(pTyr857), AKT (pSer473) and Mek1/2
were purchased from Cell Signalling Technology. Anti-STAT1 and anti-STAT3 antibodies and phos-
phospeciﬁc antibodies for STAT5 (pTyr694) and PLCγ1 (pTyr783) were obtained from BD Biosciences.
Antibodies against STAT5 (C-17), PDGFRα (C-20), ERK1 (C-16), ERK2 (c-14), AKT1/2 (N-19) and tubulin
Table 2
primers used for qPCR analysis.
Targeted gene Primers sequences
GAPDH gtccttccacgataccaaagt
atgagaagtatgacaacagcct
HPRT tggacaggactgaacgtctt
gagcacacagagggctacaa
PPIA/cycloA cagacaaggtcccaaagaca
ccattatggcgtgtgaagtc
Tubulin agatcggtgccaagttctg
ccacctgtggcttcattgta
ETV4 gcccctcgactctgaagat
tggaaatcaggaacaaactgc
ETV5 atccccgattatactttgacg
agaagggtgaccaggaactg
Kit acaaagagcaaatccatccc
tgtaggtcagaatcatcacaataat
egr1 agtggtttggctggggtaa
ctacgagcacctgaccgc
sprty2 ttgcacatcgcagaaagaag
ggtcactccagcaggcttag
sprty4 gggagccactgagaacagag
tggctcctaaatccatcctg
C. Bahlawane et al. / Data in Brief 9 (2016) 828–838836(DM1A) were bought from Santa Cruz. Anti-CD117 (KIT) antibody was obtained from Dako and
horseradish peroxidase-conjugated secondary antibodies from Cell Signalling Technology. Signals
were detected on a Fusion-FX7 chemiluminescence detection device (Vilber) using a home-made ECL
(Enhanced ChemiLuminescence) solution containing 2.5 mM luminol, 2.6 mM hydrogenperoxide,
100 mM Tris/HCl pH 8.8 and 0.2 mM para-coumaric acid [6]. Signal intensities were quantiﬁed using
the Bio1D analysis package (Vilber).
2.3. Microarray analysis
293FR cells expressing KIT-WT, KIT Ex11 deletion mutant and KIT Ex9 mutant were incubated with
5 ng/ml doxycycline and 100 ng/ml SCF for 21 h in DMEM with 1%FCS. Cells were then starved for 3 h
(without FCS) and further stimulated with SCF. RNAs of three biological replicates were isolated using
the miRNeasy Mini KIT (Qiagen) according to manufacturer's instructions with additional on-column
DNase I digestion. RNA quality and purity were assessed using a Nanodrop Spectrophotometer (Thermo
Scientiﬁc) and Agilent 2100 Bioanalyzer (Nano KIT). Gene Expression analysis was performed using
GeneChip Human Gene ST 2.0 arrays (Affymetrix). Quality control and data normalization were per-
formed as previously reported [3,7]. We focused on differentially expressed genes (DEG) across the
mutants comparing with non-stimulated KIT-WT. To exclude non-relevant lowly expressed transcript
clusters, only those showing log2 expression above 4.5 were kept for further analysis. Transcript clusters
were further summarized in order to obtain a single expression value for each gene in each experiment.
Table 3
KIT Ex11 deletion mutant speciﬁc DEG, with FDRo0.05 and absolute logFC40.5.
ACER2 CCNYL1 EYA1 IRX4 LOC401321 NKX3-1 RN5S217 SNORA10 UTRN
ADAMTS20 CD109 FAHD1 ITGA2 LOC642838 NLRP1 RN5S335 SNORA16B VRK3
ADCK3 CD3EAP FAM46A JAM2 LOC645166 NOA1 RND2 SNORA2A WDR63
ADCY1 CD68 FAM47A JMY LPAL2 NR1D2 RNF167 SNORD111 WDR77
AKAP8 CDC25B FAM59A KCNA3 LPCAT2 NRN1 RNFT1 SNORD126 WWP2
ALDH1L2 CDT1 FAM64A KDELR1 LPHN3 OLIG2 RNU2-7P SNORD3C ZC3H6
ALG12 CES3 FAM83B KDELR3 LPPR4 PABPC1L RNU7-6P SNORD60 ZFP14
AMIGO2 CHEK2 FBXO32 KIAA0355 LRFN1 PAMR1 RPL13P5 SNORD71 ZNF140
ANKRD18DP CITED1 FLJ44342 KIAA1430 LURAP1L PAQR4 RYR2 SNORD91A ZNF17
ANKRD20A12P CKMT1A FLJ45248 KIAA1609 LYSMD2 PARK2 SAMD15 SRCRB4D ZNF239
ANKRD20A5P CNN2 FRAT2 KLF11 MALAT1 PARM1 SCARA5 TAS2R31 ZNF280B
ANKRD27 CNTNAP3B GALNT6 KLHL24 MCL1 PARP14 SCARNA21 TBX15 ZNF296
ARHGAP20 CPEB4 GGA2 KLHL36 MCM5 PARP4 SEMA6A TCF25 ZNF347
ARHGAP35 CPPED1 GLTSCR2 KLRAP1 MDM2 PBX1 SERPINB1 TFAP4 ZNF485
ARHGEF1 CRKL GRAMD4 LCMT1 MED12L PCDH7 SGK1 THOC6 ZNF502
ARNT2 CRYBB2P1 GSPT2 LIG4 MGARP PDP1 SGSM3 TIGD4 ZNF574
ASRGL1 CSDA GYPC LIN37 MGST1 PDPR SHKBP1 TMEM143 ZNF581
BACE1-AS CYP2S1 GYS1 LINC00282 MIR22HG PHKB SHMT2 TMEM159 ZNF70
BBIP1 CYP41 H2BFXP LNP1 MIR3143 PKIA SLC35B2 TMEM185B ZNF738
BCL6 DDTL HIST1H2BG LOC100130776 MIR338 PLA2G7 SLC44A2 TMEM238 ZNF836
BEX5 DEDD2 HIST1H3A LOC100132439 MIR3671 PLXNA2 SLC45A3 TNFRSF10D ZSCAN12P1
BRD2-IT1 DLC1 HIST1H3H LOC100133985 MIR4263 PMFBP1 SLC6A6 TNFRSF13C
BZW1 DMRTA1 HLA-DRB5 LOC100272228 MIR4324 PPP1R13L SLC7A6OS TNRC6B
C10orf10 DYNLL2 HSDL1 LOC100287628 MIR4530 PPP1R14C SLC8A1 TOM1
C10orf25 EBF3 IER5 LOC100288018 MIR4773-2 PROX1 SLC9A1 TP53I13
C19orf54 ECH1 IFITM3 LOC100288520 MIR548A2 PRPH SLC9A2 TRBV23OR9-2
C22orf13 EID3 IGHD2-21 LOC100507299 MRI1 PRR12 SLC9A9 TRBV6-9
C2orf77 EIF1 IL11 LOC147670 MTRF1L PSEN2 SMOC1 TRPC1
CABIN1 ELAC1 ILDR2 LOC147727 MTSS1 RAB39B SMPD1 TRPS1
CABLES1 EMR2 IMPA2 LOC284648 NFIX RBL2 SNAR-D TSC2
CAMLG EPHX4 INPP5D LOC399815 NIPSNAP1 RHBDF1 SNAR-H TSSK3
CAP2 EPS15L1 IQCH LOC400927 NIPSNAP3A RN5S180 SNN TXNDC17
C. Bahlawane et al. / Data in Brief 9 (2016) 828–838 837The differentially expressed genes were statistically evaluated by two-factor linear model with
empirical Bayes statistics approach using limma package of R/Bioconductor [8]. In order to correct for
the false discovery rate (FDR), the Benjamini and Hochberg step-up method correction was applied.
Probe-sets with FDR o0.05 and absolute fold change 40.5 were considered to be signiﬁcantly dif-
ferentially expressed (DEGs). Microarray data are available in the ArrayExpress database (www.ebi.ac.
uk/arrayexpress) under accession number E-MTAB-4548. KIT Ex11 speciﬁc gene signature was deter-
mined by comparing KIT Exon 11 deletion mutant regulated genes to other GIST mutants (PDGFRA
mutants and KIT Exon 9). 277 genes.
2.4. Nuclear extract preparation
Nuclear extracts were prepared as previously done [4]. In brief, cells were washed with ice-cold
PBS, harvested gently with cell scraper and centrifuged at 4 °C for 5 min, 4000 rpm. The pellet was
then resuspend in Buffer A (10 mM Hepes/KOH pH7.9, 1.5 mM MgCl2 and 10 mM KCl). Following
10 min incubation on ice, samples were centrifuged at maximum speed, 4 °C for 5 min. The operation
was performed a second time and the pellets were ﬁnally resuspended in Buffer C for nuclear
extraction (20 mM Hepes/KOH pH7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA and 25% glycerol).
Protein concentrations were determined using Bradford reagent before analysis by western blotting.
2.5. Synergy analysis
Synergy between Receptor Tyrosine kinase (RTK) and MEK inhibitors were performed at constant
ratio, as recommended by Chou et al. [5,9]. GIST primary cells were seeded in 96 well plates 24 h prior
C. Bahlawane et al. / Data in Brief 9 (2016) 828–838838treatement. Inhibitors were added at concentration between 5 nM and 13 μM, either alone or in
combination to a ﬁnal volume of 90 μL. Endpoint viability was assessed using PrestoBlue (Thermo-
ﬁscher), by adding 10 μL of reagent to each well. Following 30 min incubation, ﬂuorescence intensities
were recorded on a CLARIOstar microplate reader (BMG LABTECH). Inhibition was then calculated as a
ratio to the non-treated samples.Acknowledgements
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